September 30, 2017

Neuroendocrine Cancer Regional Conference

Buffalo Marriott Niagara 1340 Millersport Highway Amherst, New York 14221

R MILE

Registration Fees: \$60 for physicians \$30 for other medical professionals FREE for residents, fellows & students *RPCI use special code*

HAN

J HANK



Roswell Park Cancer Institute designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit(s)[™]

N ZNL

AGENDA

Saturday – September 30, 2017

8:15 am – 8:45 am	Registration & Breakfast
8:45 am – 8:50 am	Welcome & Opening Remarks – Kari Brendtro & Srinevas Reddy
8:50 am - 10:00 am	SESSION 1 : Diagnostic Approaches & Surveillance
	General Overview – Sunyoung Lee, MD
	Principals of Pathology for Diagnosis of Pancreatic & Intestinal NETs – Jon Strosberg, MD
	Imaging Modalities and Applications
	 Optimizing Anatomical/Cross-sectional Imaging – Charles Roche, MD Choosing the Right Modality & Sequence Staging & Treatment Selection
	 Molecular Imaging - Daniel Pryma, MD Functional Imaging: Role & Limitations Diagnosis & Staging Imaging Algorithm, Appropriate Use Criteria & NCCN Guidelines Evolving Role of Nuclear Medicine Imaging & Current Clinical Trials Q & A (15 min)
10:00 am - 11:10 am	SESSION 2 : Surgical Challenges & Controversial Issues for Management of NETs
	Surgical Assessment – Moshim Kukar, MD O Goal of Surgery O Patient Selection (Age, Performance Status, Co-morbidities) O Preoperative Evaluation

	 Preoperative Evaluation Do Symptoms Influence Surgical Decisions? Should Liver Lesions be Resected at Time of Primary Surgery?
	 Open vs Laparoscopic Resections – Which is the Optimal Strategy? Small Bowel NET- Moshim Kukar, MD Use of Octreotide – Is it Necessary? Surgical Approach Prophylactic Cholecystectomy Pancreatic NET – Steven Hochwald, MD Functional vs Nonfunctional Segmental Resections - What is the Criterion? Distal Pancreatectomy (w/wo splenectomy) Panreaticoduodenectomy Surgical Exploration – Lindy Davis, MD High Grade – Should Surgery Be Considered? Unknown Primary – Is it Important to Find It?
	 Onknown Primary – Is it Important to Find It? Contraindications Hepatic Surgery for Metastatic NETs – Srinevas Reddy, MD Survival Advantages & Other Benefits of R0, R1 & R2 Resections Hepatic Resections & Liver Directed Therapy Evolving Role of the NET Surgeon – Srinevas Reddy, MD Recurrence of Metastases Peritoneal and Diaphragmatic Metastases Nodal Management
11:10 am – 11:25 am	BREAK
11:25 am – 12:20 pm	SESSION 3: Therapies for Symptom & Tumor Control
	 Carcinoid Syndrome Symptom Control - Hassan Hatoum, MD Somatostatin Analogs (SSA's - octreotide, lanreotide) Mechanisms of Action Long Term Use Refractory Diarrhea SSA's Role in Disease Stabilization
	 Other Symptom Control – Hassan Hatoum, MD Managing Persistent/Recurrent Diarrhea Not Associated with Carcinoid Syndrome Pancreatic Insufficiency from SSA Use (Pancreatic & Digestive Enzymes) Biliary Salt Malabsorption, Short Gut Syndrome, Bacterial Overgrowth Nutritional Support

	Medical Management for Progressive Disease- Thorvadur Halfdanarson, MD
	GI NETS
	 mTOR Inhibition Mechanisms of Action RADIANT 4 – (Everolimus)
	Anti-angiogenic Therapy O Bevacizumab
	Other Combination Therapies O Use with SSA's
	Pancreatic NETs
	 Targeted Therapies Tyrosine Kinase Inhibitors (Sunitinib) mTOR Inhibition – (Everolimus)
	 Chemotherapy Temozolamide Streptozosin Combination Therapies
	Poorly Differentiated NETs
	 Heterogeneity Differences in Clinical Behavior Nordic Study New WHO Classification? Platinum Based Therapies
	 Capecitabine/Temozolomide Combination
	Current Clinical Trials Q & A (10 min)
12:20 pm – 12:30 pm	SESSION 4: Roswell Park NET Registry – Renuka Iyer, MD
· · ·	
12:30 pm – 1:00 pm	SESSION 5: Case Presentations – Small Bowel & Pancreatic NET (Moshim Kukar/Thorvadur Halfdanarson)
1:00 pm – 1:30 pm	LUNCH
1:30 pm – 2:30 pm	SESSION 6: Pulmonary NETs: Challenges in Diagnosis and Management
	 Overview & Diagnosis -Renuka Iyer,MD Epidemiology Pathology Differential Diagnosis
	Surgical Resection – Sai Yendamuri, MD O Localized Disease in Peripheral O Localized Disease in Central Airway

	 Localized Disease in Central Airway Systemic Nodal Dissection Local Resection - When should Endobronchial or Peripheral Ablation be Considered? Metastatic Disease Recurrent Disease
	 Medical Therapy – Thorvadur Halfdanarson, MD Control of Hormonal Symptoms & Tumor Control Adjuvant Therapies Targeted Therapies Chemotherapy
	• Follow-up
	Future Considerations & Current Clinical Trials
	Q & A (10 min)
2:30 pm – 3:00 pm	SESSION 7: Radiolabeled Peptides - A New Era in Treatment of NETs – Jonathan Strosberg, MD
	 Background & European Clinical Experience Selection Criteria Risk Factors Krenning Score >2 Type of Previous Treatments NETTER 1 Trial – Study Objectives & Design Preventing Toxicities & Nausea Kidney Protection (Amino Acid Infusion) Radiation or MDS Where Should PRRT Be in the Treatment Paradigm? Get Prepared Future Directions & Current Clinical Trials Q & A (10 min)
3:00 pm	Closing Remarks & Adjourn – <i>Renuka Iyer, MD</i>